drugset / Trial / NCT02422641
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
Phase 2
Recruiting
16 enrolled
Wake Forest University Health Sciences
National Cancer Institute (NCI) · collabSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective evaluation of systemic, intravenous high-dose methotrexate (HD-MTX, 8 g/m2) in patients with triple negative, HER2-positive, and hormone refractory breast cancer with leptomeningeal metastasis (LMD) with or without brain parenchymal involvement.
Timeline
- Start
- 2015-05
- Primary completion
- 2026-09
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methotrexate | Small molecule | 8000 mg/m2 | Intravenous |